Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

Patrick G. Kehoe(University of Bristol), Bernadette McGuinness(Queen's University Belfast), Josephine Barnes(UK Dementia Research Institute), Vivek Pattan(NHS Forth Valley), Nicholas Turner(University of Bristol), Eric M. Jackson(Johns Hopkins University), Nick C. Fox(NIHR Queen Square Dementia Biomedical Research Unit), Ian B. Wilkinson(Oncotherapeutics (United States)), Matthew P. Sheridan, Tobias Langheinrich, Alan Thomas(UK Dementia Research Institute), Robert Barber(University of North Texas), Casper Nielsen(UK Dementia Research Institute), Suvarna Wagle, Rupert McShane(Oxford Health NHS Foundation Trust), Henk Mutsaerts(Amsterdam Neuroscience), Lucy Calvert, Carole H. Sudre(King's College London), Yoav Ben‐Shlomo(University of Bristol), Andrew J. Byrne, Lina Jarutyte(University of Bristol), Andrew Donaldson(University of Cape Town), Beth Howden(University of Bristol), Stephen Pearson(Devon Partnership NHS Trust), Peter Passmore(Queen's University Belfast), Tarun Kuruvilla, Madhusudan Dalvi, David M. Findlay(The University of Adelaide), Gordon W. Duncan(Western General Hospital), Ian B. Malone(UK Dementia Research Institute), Jodi Taylor(University of Bristol), Shona Clegg(UK Dementia Research Institute), Ajay Macharouthu(Crichton Royal Hospital), Peter Connelly(Queen's University Belfast), David L. Thomas(University College London), Ngoc Jade Thai(University of Bristol), Bernard Udeze, Aileen Wilson(University of Bristol), Alasdair Lawrie, Kirsty Harkness(Royal Hallamshire Hospital), Wendy Neil, Elizabeth Coulthard(North Bristol NHS Trust), Rashi Negi, Peter S Blair(University of Bristol)
The Lancet Neurology
October 22, 2021
Cited by 59


Related Papers